The Korean Association of Resident Physicians, in collaboration with the medical overseas expansion platform K-DOC and the Korea Health Industry Development Institute's US office, is pleased to announce the participation of Dr. Park Je-yeon, a resident in internal medicine at Seoul National University Hospital (R3), in the "Short-Term Medical Training Certificate (SMTC)" program.
From October 26, 2022, for a duration of 16 days, Dr. Park took part in the "International Observerships in Boston," where she had the opportunity to visit leading institutions including ASIMOV Bioengineering Company, Dana-Farber Cancer Institute, GENOSCO, Hanwha Group's Boston Office, K2B Therapeutics, Yuhan USA, LG Chem, Standigm, Massachusetts General Hospital (MGH), Harvard Medical School, Beth Israel Deaconess Medical Center, Massachusetts Institute of Technology (MIT), and Merck. During her visit, she explored the latest trends in the medical industry and new drug development, sharing her insights through the Medical Association Newspaper.
This short-term training program allowed Dr. Park to meet and exchange valuable experiences with Korean doctors active in universities, hospitals, research institutes, and corporations in the United States. Her reflections on the contributions of Korean doctors in the field of new drug development were highlighted as particularly enriching.
K-DOC aims to facilitate such valuable exchanges and further contribute to promoting the excellence of Korean medical professionals within the global healthcare community. We are committed to leading efforts to elevate the standards of Korean healthcare through various international collaborations.
Thank you.
The Korean Association of Resident Physicians, in collaboration with the medical overseas expansion platform K-DOC and the Korea Health Industry Development Institute's US office, is pleased to announce the participation of Dr. Park Je-yeon, a resident in internal medicine at Seoul National University Hospital (R3), in the "Short-Term Medical Training Certificate (SMTC)" program.
From October 26, 2022, for a duration of 16 days, Dr. Park took part in the "International Observerships in Boston," where she had the opportunity to visit leading institutions including ASIMOV Bioengineering Company, Dana-Farber Cancer Institute, GENOSCO, Hanwha Group's Boston Office, K2B Therapeutics, Yuhan USA, LG Chem, Standigm, Massachusetts General Hospital (MGH), Harvard Medical School, Beth Israel Deaconess Medical Center, Massachusetts Institute of Technology (MIT), and Merck. During her visit, she explored the latest trends in the medical industry and new drug development, sharing her insights through the Medical Association Newspaper.
This short-term training program allowed Dr. Park to meet and exchange valuable experiences with Korean doctors active in universities, hospitals, research institutes, and corporations in the United States. Her reflections on the contributions of Korean doctors in the field of new drug development were highlighted as particularly enriching.
K-DOC aims to facilitate such valuable exchanges and further contribute to promoting the excellence of Korean medical professionals within the global healthcare community. We are committed to leading efforts to elevate the standards of Korean healthcare through various international collaborations.
Thank you.